Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Guidance On B. Cepacia Contamination Coming Soon, CDER Director Cavazzoni Says

Executive Summary

Agency will provide guidance in wake of recent outbreaks of Burkholderia cepacia in non-sterile, water-based drug products.

You may also be interested in...



Draft US FDA Guidance Outlines Heightened Expectations On Sterility Of Non-Sterile Drugs

More testing expected after B. cepacia contamination of OTC liquid drug products, including for Rx drug products.

The Quality Lowdown: Enforcement And Compliance During A Lingering Pandemic

US FDA oversees plants straining to meet demand for COVID-19 vaccines and treatments, while cracking down on adulterated hand sanitizers.

B. Cepacia Hits ICUs Again, Raises Manufacturing Controls Questions

Another outbreak of B. cepacia at hospital intensive care units in multiple states implicates manufacturing and supply chain controls on aqueous non-sterile drug products, particularly for those marketed over the counter under OTC monographs.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel